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Abstract
Background: Currently there is no framework for those involved in the identification, evaluation and prioritisation of 
new diagnostic technologies. Therefore we aimed to develop prioritisation criteria for the assessment of new 
diagnostic technologies, by gaining international consensus on not only which criteria should be used, but also their 
relative importance.
Methods: A two-round Delphi process was used to generate consensus amongst an international panel of twenty-six 
experts on priority criteria for diagnostic health technology assessment. Participants represented a range of health care 
and related professions, including government, industry, health services and academia.
Results: Based on the responses to the first questionnaire 18 criteria were placed into three categories: high, 
intermediate and moderate priority. For 16 of the 18 criteria, agreement with the categorisation of the criteria into the 
high, intermediate and moderate categories was high at ≥ 70% (10 had agreement ≥ 80%). A further questionnaire and 
panel discussion reduced the criteria to 16 and two categories; seven were classified as high priority and nine 
intermediate.
Conclusions: This study proposes an objective structure of prioritisation criteria to use when assessing new diagnostic 
technologies, based on an expert consensus process. The value of these criteria is that no one single component 
should be used as the decisive driver for prioritisation of new diagnostic technologies for adoption in healthcare 
settings. Future studies should be directed at establishing the value of these prioritisation criteria across a range of 
healthcare settings.
Background
A correct diagnosis is central to guiding choice of treat-
ment, monitoring the effects of that treatment, as well as
determining prognosis. Diagnosis involves both clinical
skills (e.g. physical examination), as well as techniques to
measure physiological parameters (e.g. blood pressure),
and biochemical, haematological, other pathological and
radiological investigations. New diagnostic technologies
are continually being developed and marketed, while
technologies that are currently used in hospital or tradi-
tional laboratory settings are increasingly being repack-
aged as point of care devices. However, improvements in
diagnostic technologies do not inevitably translate to
benefits to patient care [1]. For example, a new test may
not have a clearly defined role in an existing diagnostic
pathway, or may simply contribute to diagnostic uncer-
tainty. Unlike randomised trials of interventions, which
have a control arm, most studies of diagnostic accuracy
do not compare the outcome from the use of the new test
with existing tests [2].
In order for health care purchasers and providers to
assess the importance and role of a new diagnostic tech-
nology in the diagnostic pathway, it is vital to have a pro-
cess that can identify which technologies require more
detailed or formal assessment, such as technology assess-
ments or evidence-based summary reports. Simply using
the efficacy data of a new diagnostic technology derived
from a clinical study to determine adoption in the health-
care setting is inadequate [3]. This approach does not
take into account all the factors influencing adoption of a
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test, such as the clinical setting, disease prevalence and
proposed use.
Prioritising health technologies for further assessment,
particularly for therapeutic interventions, is well estab-
lished among international health technology assessment
(HTA) bodies. Priority setting has involved both quanti-
tative methods or scoring systems [4], as well as consen-
sus guidelines. Quantitative models have been developed,
for example by the Institute of Medicine in the USA, who
developed a specific quantitative method to calculate pri-
ority scores based on criterion weight, as well as scores
proposed by the Committee on Priorities for Assessment
and Reassessment of Health Care Technologies [4], and
the Technology Assessment Priority-Setting System
(TAPSS) developed by the Council on Health Care Tech-
nologies [5]. In Europe, the EEC-funded EUR-ASSESS
project for the coordination of HTA activities produced a
set of guidelines for the priority setting of HTA projects
[6]. Indeed, a recent systematic review identified 12 dif-
ferent priority setting frameworks used among 11 inter-
national HTA agencies, with a total of 59 different
priority setting criteria [7]. Although the existing frame-
works are intended to be applied to all technologies, there
is a paucity of guidance on methods for prioritising diag-
nostic technologies in particular.
There are several reasons why diagnostic technologies
require prioritisation criteria that are distinct from exist-
ing frameworks. Diagnosis usually involves a pathway in
which a new technology may have a variety of roles such
as replacing an existing test, triaging, or as an add-on test.
In addition diagnostic accuracy may vary widely between
different clinical settings and populations due to varia-
tions in prevalence and spectrum of disease. Key issues
that are important in the evaluation of new diagnostic
technologies have been proposed previously - these fitted
into three broad domains, those related to the disease or
target condition, the new diagnostic technology itself,
and the impact of the diagnostic technology [8]. To
address the important gap in the technology prioritisa-
tion of diagnostic technologies we aimed to build on
these criteria, by refining them and including additional
criteria. We also aimed to assess the criteria systemati-
cally by developing an international consensus on not
only which criteria should be used to prioritise diagnostic
technologies, but also their relative importance.
Methods
We used the Delphi method, which is an objective pro-
cess that gathers consensus opinion from a panel of
experts through an iterative questionnaire process inter-
spersed with controlled opinion feedback [9]. Panels gen-
erally involve 10 to 50 members and experts who are
anonymous, in that other panel members do not know
their identity at the time of data collection. The Delphi
method has been used extensively in developing criteria
frameworks [10,11]. No ethical approval was required for
this study.
We identified an international group of experts as fol-
lows: (1) membership of early awareness and alert net-
works (e.g. The International Information Network on
New and Emerging Health Technologies [EuroScan]), (2)
recommendation from researchers in the field of health
technology assessment, (3) contacts in diagnostic tech-
nology industries, (4) contacts in government bodies
tasked with health technology assessment, and (5) rec-
ommendations from researchers and providers in the
field of primary health care and diagnosis. Experts were
contacted by email and invited to contribute to the study
using either email or a web-based format and were from a
variety of health care sectors and related professional dis-
ciplines (Table 1).
The first questionnaire used prioritisation criteria
developed by Summerton [8], which were compiled into
an initial questionnaire following preliminary discussions
amongst a small group of experts. The initial question-
naire consisted of 18 criteria, which were grouped into
those pertaining to (1) the disease or target condition, (2)
the new diagnostic technology, and (3) the impact of the
diagnostic technology (Table 2). Participants were asked
to rate the importance of, or their level of agreement
with, each criterion using a seven-point Likert scale,
where 1 indicated low and 7 high importance or levels of
agreement. Open comments or clarifications on each
item, as well as general comments and suggestions
regarding items overlooked in the questionnaire were
solicited. In total 26 respondents participated in the first
questionnaire.
Responses to the first questionnaire were categorised
according to the proportion of respondents that ranked
criterion as a 6 or 7 on the Likert scale. Based on this
analysis three priority groups were created: (1) high pri-
ority, at least 70% of respondents ranked 6 or 7, (2) inter-
mediate priority, 50-69% of respondents, and (3)
moderate priority, less than 50% of respondents.
A second questionnaire was then developed, placing
the criteria in the aforementioned three priority groups.
The experts were informed of the method used to group
the criteria and were asked to indicate whether they
agreed or disagreed with the placement of each criterion
into its respective priority group. If they disagreed with
the placement of a criterion, they were asked to suggest
which category the criterion should be placed into (high,
intermediate or moderate) and provide clarifying com-
ments for their opinion. General comments were also
invited. The final questionnaire responses were reviewed
at a focus panel meeting of a smaller group of experts.Plüddemann et al. BMC Health Services Research 2010, 10:109
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Results
The 26 respondents represented a broad section of the
health care sector: government (10%), industry (24%),
academic (28%) and health services (38%), with diverse
professional roles (Table 1). In some instances partici-
pants had more than one professional role and/or worked
for different sectors (e.g. health care services and aca-
demic).
Round 1 Questionnaire
For 5 of the 18 criteria in the first questionnaire (Table 2;
criteria 1, 3, 9, 15, 16), we found a high level of consensus
existed as to their prioritisation importance. For example,
88% of respondents assigned a high importance to "The
potential that the technology will have an impact on mor-
bidity and/or mortality of the disease" and 85% to "The
new technology reduces the number of people falsely diag-
nosed with the disease or target condition". Although 73%
of respondents ranked "The disease or target condition to
which the diagnostic technology will be applied can be
clearly defined" as a 6 or 7 on the scale of importance,
13%, primarily from the academic sector, considered this
criterion unimportant, ranking it as 1 or 2 on the Likert
scale.
Seven criteria (Table 2; criteria 2, 4, 6, 8, 14, 17, 18)
showed a substantial variation in ranking of their impor-
tance. For example, 46% of respondents assigned a low
level of importance to "The relevance of the disease or tar-
get condition to current regional or national health poli-
cies and/or priorities", with 23% scoring a 1 or 2, whereas
23% rated this criterion as important, scoring a 6 or 7.
Respondents ranking this criterion as being of low impor-
tance (1 or 2 on the Likert scale) came from academic,
industry and health services sectors, whereas respon-
d e n t s  f r o m  t h e  g o v e r n m e n t  s e c t o r  g a v e  t h i s  c r i t e r i o n
more importance (4 to 6 on the Likert scale). Reasons
provided for rating this criterion low included: regional
and national policies are sometimes out-of-date, priori-
ties can be skewed by political pressure, and it is most
important how much morbidity and mortality can be
avoided rather than whether it is a government priority.
However some respondents from industry and academia
ranked this criterion as a 7 in terms of its importance.
Regarding "The prevalence or incidence of the disease or
target condition", respondents commented uncommon
conditions could still be important to consider for
research. "It would be feasible to change current practice
to incorporate this technology (e.g. additional training,
infrastructure, or quality control)" showed the most rank-
ings of 5, indicating that this criterion was deemed some-
what important, but not the most important.
"The potential that the technology will have an impact
on morbidity and/or mortality of the disease" scored the
highest mean Likert value of 6.5 and the criterion that
"The relevance of the disease or target condition to current
regional or national health policies and/or priorities" had
the lowest mean value of 4.2. Based on the responses to
the round 1 questionnaire, we categorised the criteria
into high (70% or more respondents ranked criteria as 6
or 7 on the scale of importance), intermediate (50-69%
ranked criteria as 6 or 7 on the scale of importance) and
moderate priorities (less than 50% ranked criteria as 6 or
7 on the scale of importance) for the second round ques-
tionnaire.
Round 2 Questionnaire
A total of 24 (92%) of those who participated in the first
questionnaire responded to the second questionnaire. For
16 of the 18 criteria, agreement with the categorisation of













Health Technology Assessment 5
Marketing 2
Consultancy 1
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Table 2: Criteria appraised by experts: Round 1 Questionnaire
Percent ranking 6 or 7
Regarding the disease or target condition
1. The disease or target condition to which the diagnostic technology will be applied can be clearly defined. 73%
2. The prevalence or incidence of the disease or target condition. 58%
3. The potential that the technology will have an impact on morbidity and/or mortality of the disease or target condition. 88%
4. The relevance of the disease or target condition to current regional or national health policies and/or priorities. 23%
5. The accuracy of the current diagnostic approach for the disease or target condition is problematic. 65%
6. There is variation in treatment or patient outcomes resulting from current diagnostic variability. 58%
7. The current diagnostic pathway for the disease or target condition could be improved by obtaining information in a 
less risky fashion or in a manner more acceptable to patients.
65%
Regarding the new diagnostic technology
8. The new technology has a clearly defined role in the diagnostic pathway, e.g. replacing an existing test, as a triage tool, 
or after the diagnostic pathway as an add-on test.
58%
9. The new technology improves the ability to rule out the disease or target condition. 77%
10. The safety profile of the new technology has been established. 62%
11. There is evidence of test accuracy in the setting in which the new diagnostic technology will be applied. 70%
12. The new technology improves the ability to rule in the disease or target condition. 62%
13. The new technology would enhance diagnostic efficiency or be more cost effective than the current diagnostic 
approach.
65%
14. It would be feasible to change current practice to incorporate this technology (e.g. additional training, infrastructure, 
or quality control).
46%
15. The new technology reduces the number of people falsely diagnosed with the disease or target condition. 85%
Regarding the impact of the diagnostic technology
16. Improved diagnostic precision using the technology would lead to improvement(s) in the delivery of treatment (e.g. 
shorter time to initiating treatment, reduction in morbidity or mortality).
81%
17. The new diagnostic technology will decrease workload in managing the disease or target condition. 35%
18. The cost-effectiveness of the new technology compared to existing standard practice. 50%Plüddemann et al. BMC Health Services Research 2010, 10:109
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the criteria into the high, intermediate and moderate cat-
egories was high at ≥ 70% (10 had agreement ≥ 80%).
There was low agreement for two criteria: "The preva-
lence or incidence of the disease or target condition" (54%
agreement) and "There is variation in treatment or
patient outcomes resulting from current diagnostic vari-
ability" (67% agreement). For the latter, a number of
respondents commented it should be moved from the
intermediate to high priority groups, since practice varia-
tion is an important driver of prioritisation and variation
in outcomes is a clear sign that the current diagnostic
process is not fit for purpose. For "The prevalence or inci-
dence of a disease or target condition", several experts dis-
agreed with its placement into the intermediate category
and suggested it should have a high priority. The main
reason given for this was technologies that have an
impact on highly prevalent diseases would have the great-
est impact within the health care system. However, other
experts felt this criterion should be moved to moderate
priority, as they considered that it would not be a useful
criterion in itself if the technology did not meet any of the
other criteria.
Several experts also suggested moving the criteria
placed into the "moderate priority" category into either
the high or intermediate priority categories. Based on the
subsequent panel discussion, there did not appear to be a
clear reason to differentiate between intermediate and
moderate priority categories, so these were combined.
Two criteria were removed from the final list as several
respondents commented that they overlapped with other
criteria. These were the criteria relating to cost-effective-
ness and workload, which were already addressed by "The
new technology would enhance diagnostic efficiency or be
more cost effective than the current diagnostic approach".
The latter criterion was then moved to high priority, in
line with expert suggestions. The final list consisted of 16
criteria, seven of which were considered high priority and
nine of intermediate priority (Table 3).
Discussion
In this study we have developed prioritisation criteria for
the evaluation of new diagnostic technologies. With the
aid of a two-round Delphi consensus method, which
sought the opinions of 26 experts, 16 criteria were agreed,
of which seven were classified as high priority and nine as
intermediate priority. To our knowledge this is the first
study to address prioritisation criteria for diagnostic
technologies using the Delphi method.
This study was designed to canvass opinions from a
range of experts from industry, academia, government
and health services. The aim of such a process is to obtain
a range of opinions from diverse perspectives and, unlike
quantitative surveys, does not rely on a large sample to
determine outputs with confidence. Although our list of
experts is not exhaustive, the group provided a wide
range of views and represented several different sectors.
The prioritisation criteria presented are therefore not
dependent on the views of professionals from one specific
constituency or working in a particular health care sys-
tem or country. However, we acknowledge that the gener-
alisability of the findings of the Delphi consensus
approach may be limited by the relatively small number
of participants, who may have specific views or agendas.
Further studies to verify and refine our results in different
or extended groups of participants should be considered.
A wide range of quantitative and qualitative prioritisa-
tion criteria for health technologies have been published
by committees and organisations involved in health care
[5,7]. Generally the criteria lists share three main ele-
ments: (1) clinical impact, (2) economic impact and (3)
budget impact. A weighted benefit score coupled with
cost for prioritising health technologies at the primary
care trust level was developed by Wilson et al [12]. The
authors applied this score to six proposed services and
found that it was practical, however ultimately the pri-
mary care trust was not able to use the results of the score
as the sole criteria to prioritise which services to fund.
Indeed, two of the prioritised services did not receive
funding, indicating that the criteria were inadequate. A
systematic review of 12 priority-setting frameworks from
11 agencies in 10 countries highlighted differences across
HTA agencies regarding categorisation, scoring and
weighting of criteria [7]. The review showed that quanti-
tative rating methods and cost benefit considerations for
priority setting were seldom used.
Although criteria have been developed for priority set-
ting of new health technologies for early assessment,
these are generally applied to novel therapeutic agents
and interventions [13]. Selection criteria also differ signif-
icantly depending on the early awareness programme,
and prioritisation is frequently implicit and undocu-
mented [13,14]. The requirements for diagnostic technol-
ogies are somewhat different. For example, while the
prevalence or incidence of a disease is a primary criterion
listed in many of the existing prioritisation frameworks,
the consensus emerging from our study indicates that, in
terms of diagnostic technologies, this criterion carries
less weight: a test for a relatively uncommon disease (e.g.
pancreatic cancer) may still be very important. Diagnos-
tic technologies may also have different outcomes, for
example either ruling in or ruling out a disease. Here it
emerged that ruling out a disease is of higher priority in
diagnosis, although this may not be the case in all clinical
settings: in high acuity situations, such as critical care,
ruling in a disease may be more important.
Although in some cases there was disagreement
amongst the panel regarding the placement of criteria
into their respective categories, overall the level of con-Plüddemann et al. BMC Health Services Research 2010, 10:109
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Table 3: Proposed Criteria for the Prioritisation of Diagnostic Technologies
Does the technology meet the criterion?
High Priority Yes No Unsure
1. The potential that the technology will have an impact on morbidity and/or mortality of 
the disease or target condition.
2. The new technology reduces the number of people falsely diagnosed with the disease 
or target condition.
3. Improved diagnostic precision using the technology would lead to improvement(s) in 
the delivery of treatment (e.g. shorter time to initiating treatment, reduction in morbidity 
or mortality).
4. The new technology improves the ability to rule out the disease or target condition.
5. The disease or target condition to which the diagnostic technology will be applied can 
be clearly defined.
6. There is evidence of test accuracy in the setting in which the new diagnostic technology 
will be applied.
7. The new technology would enhance diagnostic efficiency or be more cost effective 
than the current diagnostic approach.
Intermediate Priority
1. The prevalence or incidence of the disease or target condition.
2. The accuracy of the current diagnostic approach for the disease or target condition is 
problematic.
3. There is variation in treatment or patient outcomes resulting from current diagnostic 
variability.
4. The current diagnostic pathway for the disease or target condition could be improved by 
obtaining information in a less risky fashion or in a manner more acceptable to patients.
5. The safety profile of the new technology has been established.
6. The technology improves the ability to rule in the disease or target condition.
7. The new technology has a clearly defined role in the diagnostic pathway, e.g. replacing 
an existing test, as a triage tool, or after the diagnostic pathway as an add-on test.
8. The relevance of the disease or target condition to current regional or national health 
policies and/or priorities.
9. It would be feasible to change current practice to incorporate this technology (e.g. 
additional training, infrastructure, or quality control).Plüddemann et al. BMC Health Services Research 2010, 10:109
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sensus was high. The criteria set out in this study should
be relevant to those involved in identification, evaluation
and prioritisation of new diagnostic technologies at
national, regional or local levels. Our aim is to provide a
framework for the selection of new diagnostic technolo-
gies for in-depth assessment or implementation, based on
how many and the extent to which the listed criteria are
satisfied and whether they fall into the high or intermedi-
ate priority category. This could be achieved by assessing
which criteria are met via a check-list (Table 3). One stra-
tegic use of such a checklist, adopted by our Diagnostic
Technology Horizon Scanning Centre [15], is to highlight
areas where there is lack of evidence and where further
research is required. Different specialities may also apply
different weights to the criteria, depending on their prior-
ities. These criteria could be adopted by the 'Evaluation
Pathway Programme for Medical Technologies' recom-
mended in the NHS Next Stage review and currently
being established by UK National Institute for Clinical
Excellence, to which some diagnostic technologies will be
subject. In addition, they would potentially also be appli-
cable to the Agency for Healthcare Research and Qual-
ity's (AHRQ) proposed new Horizon Scanning System in
the USA [16]. Future studies should be directed at estab-
lishing the value of these prioritisation criteria in such
settings. An important challenge will be to identify the
supporting evidence base required to assess the high pri-
ority criteria in particular.
Conclusions
The prioritisation criteria presented in this study provide
an objective structure for the assessment of new and
emerging diagnostic technologies. In effect the value of
these criteria is that no one single component should be
used as the decisive driver for prioritisation of new diag-
nostic technologies for adoption in healthcare settings,
irrespective of the context. We encourage diagnostic
technology programmes to evaluate further the value of
these criteria.
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